UK markets closed
  • FTSE 100

    -63.84 (-0.91%)
  • FTSE 250

    +26.10 (+0.11%)
  • AIM

    +3.60 (+0.28%)

    -0.0007 (-0.06%)

    -0.0059 (-0.43%)

    +341.99 (+0.97%)
  • CMC Crypto 200

    -32.05 (-2.62%)
  • S&P 500

    -40.76 (-0.91%)
  • DOW

    -166.44 (-0.48%)

    -0.65 (-0.90%)

    -2.80 (-0.16%)
  • NIKKEI 225

    +176.71 (+0.58%)

    +252.91 (+1.03%)
  • DAX

    -161.58 (-1.03%)
  • CAC 40

    -52.40 (-0.79%)

Epilepsy Drugs Market, Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Growth, Opportunity Company Analysis

·4-min read

Globally, millions of people are affected by neurological disorders. In that, over 80% of the death takes place in the low and middle-income countries. Worldwide Epilepsy is the most common neurological disorder, affecting people of all ages.

New York, Aug. 26, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Epilepsy Drugs Market, Global Forecast, Impact of COVID-19, Industry Trends, by Drugs Category, Growth, Opportunity Company Analysis" -
This disease is a chronic brain disorder characterized by sudden and recurrent episodes of seizure. Patients who have epilepsy suffer from sudden behavioral changes, loss of consciousness and severe emotional distress. According to the World Health Organization (WHO), around 50 million people have epilepsy worldwide. Epilepsy is a common serious, and about 2.4 million new cases are diagnosed annually.

Besides, the rising incidence of higher birth-related injuries, neurological disorders, increasing road traffic injuries, growing disease awareness, and rising patient base in developing countries are the significant factors driving the global Epilepsy drug market. Increasing R&D investment and the launch of extended-release formulations are further expected to fuel the market growth. According to the research, the Global Epilepsy Drugs Market is projected to reach US$ 10.3 Billion by 2027.

Globally, United States is the largest epilepsy drug market due to better healthcare infrastructure and rising cases of epilepsy. As per the Epilepsy Foundation of Michigan, epilepsy is the fourth most common neurological disorder in the United States after stroke, migraine, and Alzheimer’s disease. About one percent of Americans have some form of epilepsy, and nearly four percent (which is equal to 1 in 26) will develop epilepsy at some point in their lives. Thus, there is a rising demand for effective treatment in the US, significantly boosting the growth of the epilepsy drug market.

Additionally, China, India, and Brazil were among the countries with a higher proportion of the population suffering from the condition. To minimize the burden of this disease and facilitate the availability of better treatment options, governments from various countries across the world are providing active support. According to this research report, the Global Epilepsy Drugs Industry is likely to grow at a CAGR of 5.46% during (2020- 2027).

Based on Drugs Category
The global epilepsy drugs market is segmented into First Generation, Second Generation, Third Generation, Others. The third Generation holds the largest market share; the major factors responsible for the growth of the third generation segment include the launch of highly efficacy drugs with the enhanced mechanism of action, fewer side effects and the awaited launch of new pipeline medicines. Third-generation drugs such as Vimpat, Briviact and others have penetrated the worldwide market considerably and proven to be quite effective in treating epilepsy.

On the other hand, the second-generation antiepileptic drug class, including Keppra, Fycompa and Briviact. They dominated the market due to their large tolerability and safety due to the launch of highly potent drugs, which apply novel techniques mechanisms of action. Worldwide Epilepsy Drugs Market Size was US$ 7.1 Billion in 2020.

Top players such as Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc. of Epilepsy Drugs Market focus on introducing medications that have lesser side-effects to the patients. Besides, companies are also focused on improving the potentiality of the drugs to control the symptoms of epilepsy effectively. In 2020, Eisai Co., Ltd. announced the launch of FYCOMPA in China to treat patients aged 12 years and more adults with partial-onset seizures.

This latest report “Global Epilepsy Drugs Market by Country (United States, United Kingdom, France, Germany, Italy, Spain, India, China, Japan) by Drugs Category (First Generation, Second Generation, Third Generation and Others) by Drugs (Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089) and Others) Company Analysis (Eisai Co., Ltd., UCB Inc., H. Lundbeck A/S, GW Pharmaceuticals Plc.)” Provides a detailed analysis Global Epilepsy Drugs Industry.

Country - Global Epilepsy Drugs Market have been covered from 9 Viewpoints:
1. United States
2. United Kingdom
3. France
4. Germany
5. Italy
6. Spain
7. India
8. China
9. Japan

Drugs Category - Global Epilepsy Drugs Market have been covered from 4 Viewpoints:
1. First Generation
2. Second Generation
3. Third Generation
4. Others

Drugs - Global Epilepsy Drugs Market have been covered from 9 Viewpoints:
1. Vimpat (Lacosamide)
2. Keppra (Levetiracetam)
3. Sabril (Vigabatrin)
4. Onfi (Clobazam)
5. Fycompa
6. Briviact (Brivaracetam)
7. Epidiolex
8. Cenobamate (YKP3089)
9. Others

Company Insights:
• Overview
• Company Initiatives
• Sales Analysis

Companies Covered:
1. Eisai Co., Ltd.
2. UCB Inc.
3. H. Lundbeck A/S
4. GW Pharmaceuticals Plc.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


CONTACT: Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting